Invokana Lawsuit Plaintiffs Allege Drug Is Linked To Diabetic Ketoacidosis Side Effect

February 25, 2016 – – TheProductLawyers.com reports on initial lawsuits filed against type-2 diabetes drug Invokana and manufacturer Janssen Pharmaceuticals, (a division of Johnson & Johnson corporation). The lawsuits were filed by plaintiffs who used Invokana and were since diagnosed with a life-threatening condition called diabetic ketoacidosis.

One lawsuit was filed on December 10th of 2015 in the Philadelphia Court of Common Pleas under case number 15-12-00653. The plaintiff filing this lawsuit claims that he began to take the drug in order to treat his diabetes in November of 2014, yet, only 3 months later, was diagnosed with diabetic ketoacidosis.

Ketoacidosis is a potentially life-threatening condition in which the bloodstream of the body becomes filled with too much toxic acid from ketones. The condition is especially dangerous as it has been reported to arise in as little as 24-hours and, if it remains untreated, can cause patients to go into comas or pass away.

Ketoacidosis and Invokana were the subjects of a recent announcement by the U.S. Food and Drug Administration, who is now requiring manufacturer Janssen to change the drug’s product labeling in order to better reflect this potential risk. In addition to requiring diabetic ketoacidosis to be added to the drug’s labeling, the FDA has requested that Janssen also add urinary tract infection warnings to the list, as they were commonly noted during clinical trials and have also been the subject of adverse event reports to the agency.

The other Invokana ketoacidosis lawsuit was filed by a plaintiff in the U.S. District Court for the Southern District of Alabama under case number 1:25-cv-00636. This case was filed just 5 days after the Philadelphia one, on December 15th of 2015. In this particular case, the plaintiff claims that she began taking Invokana to treat her diabetes in December of 2014, and developed ketoacidosis shortly afterward. She states that she would not have chosen to take the drug had she been made properly aware of its potential risks, and, within her lawsuit, she alleges that Janssen was negligent by neglecting to properly warn the public about these risks, and failing to adequately study the drug. In addition, she claims the company showed negligence by marketing it to her as a type-1 diabetes patient, as this is an “off-label”, non-FDA-approved use.

The attorneys at Banville Law are currently working to help anyone who may have taken Invokana and who suffered from ketoacidosis or other health issues that they believe were caused by the drug. These patients may be entitled to significant compensation, and are entitled to explore their full legal rights. To help encourage those who may have been affected to pursue their rightful justice, Banville Law is currently offering free legal consultations for affected parties. In addition, they sponsor online Invokana resource website TheProductLawyers.com, which provides current information on the drug, and others.

To request additional information, or to ask questions, please contact the attorneys at Banville Law by calling 877-671-6480

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008368